GLP1R and myotonic dystrophy type 1: This report is the first to highlight how GLP-1R gene polymorphisms may influence the therapeutic response to GLP-1R agonists in DM1 patients, suggesting that these drugs may exert a more pronounced hypoglycemic effect in DM1 patients with specific genetic backgrounds (142).